It’s like clockwork, every damn Friday afternoon. I think I’m getting out early to enjoy the weekend, anticipating the chance to get shittered on negronis, only for Health Canada to drop one of their usual Friday afternoon updates on their list of cannabis licenses.
While the hype around Libra and Bitcoin’s latest run is drawing everyone’s attention, there are real no-bullshit blockchain companies making big strides towards mainstream acceptability.
The advent of cryptocurrency has given rise to ancillary companies piggybacking off of its success. These companies have either sought to capitalize on the opportunity to profit off the cryptocurrency’s infrastructure by either mining crypto directly, controlling nodes and flow of a coin, or by acting directly as a trust.
GW Pharmaceuticals (GWPH.Q) has received a recommendation from the European Medicines Agency (EMA) for the authorization of the company’s Epidyolex cannabis oral solution for use in the treatment of seizures.
Reading Chemesis International’s (CSI.C)‘s July 26, 2019 “operational and corporate update” is like watching footage of a toddler vacuuming a living room.
Equity.Guru podcast: 1933 Industries (TGIF.C) under-valued story has a crazy market cap-to-revenue ratio
The power of pot and everything stoner were thought to be keys behind behind the eventual success of legalized cannabis, but as the market has matured, health and wellness has increasingly become the focus for many. People want more than just getting high, they want to get better.
A few years ago, we wrote one of our defining pieces at Equity.Guru, an article that opened a new world up for a variety of investors, and introduced them to a pre-public listing deal that, for a change, was opening up to the little guy.